Products
Sigvotatug Biosimilar Monoclonal Antibody (Integrin β6) for Research
Cat No.: GMP-Bios-INN-1385
Anti-ITGB6 therapeutic antibody (Pre-made Sigvotatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Sigvotatug (development code SGN-B6A) is a humanized monoclonal antibody targeting integrin beta-6 (ITGB6). It is developed by Seattle Genetics and Seagen for Non-small cell lung cancer, Solid tumours in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1385-1mg | 1mg | 3090 |
| GMP-Bios-INN-1385-10mg | 10mg | |
| GMP-Bios-INN-1385-100mg | 100mg | |
| GMP-Bios-INN-1385-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Sigvotatug biosimilar, Whole mAb, Anti-ITGB6 Antibody: Anti-Integrin beta 6/Integrin beta-6/ITGB6/AI1H therapeutic antibody |
| INN Name | Sigvotatug |
| Target | ITGB6 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Seattle Genetics;Seagen |
| Conditions Approved | na |
| Conditions Active | Non-small cell lung cancer;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
